What is wrong with clinical proteomics?
Graduate student, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada;
Ashley
A
Di Meo
Head, Division of Clinical Biochemistry, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada; Head, Clinical Biochemistry Section, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada; Biochemist-in-Chief, Department of Clinical Biochemistry, University Health Network, Toronto, Ontario, Canada; ediamandis@mtsinai.on.ca.
Eleftherios P
EP
Diamandis
Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiatives, Office of the Director, National Cancer Institute, Bethesda, MD;
Henry
H
Rodriguez
Head, Division of Clinical Chemistry, Director, Clinical Mass Spectrometry, Assistant Director, Clinical Immunology, Director, Nutrition and Obesity Research Center, Analytical Core, University of Washington, Seattle, WA;
Andrew N
AN
Hoofnagle
Chair in Disease Prevention at Stanford University, Professor of Medicine and Director of the Stanford Prevention Research Center, Stanford University School of Medicine, Stanford, CA;
John
J
Ioannidis
Director, BRIMS Center, Thermo Fisher Scientific, Cambridge, MA.
Mary
M
Lopez
D015415:Biomarkers / Q000032:analysis*; D035843:Biomedical Research / Q000379:methods / Q000639:trends*; D064790:Clinical Laboratory Services / Q000639:trends*; D006801:Humans; D025202:Molecular Diagnostic Techniques / Q000379:methods / Q000639:trends*; D040901:Proteomics / Q000379:methods / Q000639:trends*
D015415:Biomarkers